Lipitin 10mg 1pcs

Presentation
Lipitin 10: Each film-coated tablet contains Atorvastatin 10 mg (as Atorvastatin
Calcium Trihydrate USP).
Lipitin 20: Each film-coated tablet contains Atorvastatin 20 mg (as Atorvastatin
Calcium Trihydrate USP).
Lipitin 40: Each film-coated tablet contains Atorvastatin 40 mg (as Atorvastatin
Calcium Trihydrate USP).
Description
Lipitin (Atorvastatin) is a lipid-lowering agent. It inhibits selectively and competitively
the 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase. This enzyme
catalyzes the conversion of HMG-CoA to mevalonate, an early and rate limiting step
in the synthesis of cholesterol.
Indications
Lipitin (Atorvastatin) is indicated for the treatment of
v Primary hypercholesterolaemia
v Heterozygous familial hypercholesterolaemia
v Homozygous familial hypercholesterolaemia
v Combined (mixed) hyperlipidaemia
in patients who have not responded adequately to diet and other appropriate
measures.
Dosage & administration
Primary hypercholesterolaemia and combined hyperlipidaemia, usually 10 mg once
daily. Familial hypercholesterolaemia, initially 10 mg daily, increased at intervals of 4
weeks to 40 mg once daily; if necessary, further increased to max. 80 mg once daily.
Contraindications
Active liver diseases or unexplained persistent elevations of serum transaminases.
Hypersensitivity to any component of this medication. Pregnancy and lactation.
Side effects
Atorvastatin is generally well tolerated. Adverse reactions have usually been mild
and transient. The most frequent adverse events thought to be related to
Atorvastatin were constipation, flatulence, dyspepsia and abdominal pain, headache,
nausea, myalgia, diarrhoea, asthenia and insomnia.
Use in pregnancy & lactation
Safety in pregnancy has not been established. HMG-CoA reductase inhibitors are
not recommended for use during pregnancy. An interval of one month should be
allowed from stopping atorvastatin treatment to conception in the event of planning a
pregnancy.
Use of HMG-CoA reductase inhibitors during breast feeding is not recommended,
because of potential for serious adverse effects in nursing infants.
Paediatrics : Safety and efficacy of Atorvastatin has not been established in children.
Geriatrics : Efficacy and safety in older patients using recommended doses is similar
to that seen in general population.
Drug interactions
The risk of myopathy during treatment with other drugs of this class is increased with
concurrent administration of cyclosporine, fibric acid derivatives, niacin,
erythromycin, azole antifungals.
Antacid : when atorvastatin and antacid suspension were coadministered, plasma
concentration of atorvastatin decreased approximately 35% however, LDL-C
reduction was not altered.
Digoxin : When multiple doses of atorvastatin and digoxin were coadministered,
steady state plasma digoxin concentrations increased by approximately 20%.
Erythromycin : In healthy individuals, plasma concentration of atorvastatin
increased approximately 40% with coadministration of atorvastatin and erythromycin.
Oral Contraceptives : Coadministration of atorvastatin and an oral contraceptive
increased AUC values for norethindrone and ethinyl estradiol by approximately 30%
and 20%.
Storage conditions
Store in a cool & dry place away from light. Keep out of reach of children.